Drug development rests on two questions about every candidate: what the body does to the molecule, and what the molecule does to the body. Pharmacokinetics (PK) answers the first and pharmacodynamics answers the second, and neither is informative alone. Together they describe the Absorption, Distribution, Metabolism, and Excretion (ADME) profile of a drug, connect concentration to effect, and supply the data used to set dose, assess safety margins and design the first-in-human study. Prisys Biotech works on both halves of that question in Non-Human Primate (NHP) models, a species choice that shapes how far the results travel.
I. Pharmacokinetics (PK) Research: Mapping the Drug's Journey In Vivo
PK is the study of what the body does to the drug, described quantitatively as the time course of Absorption, Distribution, Metabolism, and Excretion (ADME). Clinical pharmacokinetics applies the same principles to individual patients, where the aim is a regimen that holds exposure inside a therapeutic range: enough for effect, not enough for toxicity.
The core objectives of PK studies include:
- Enhancing Efficacy and Reducing Toxicity: Guiding the rational design of dosage and frequency from the concentration-time profile.
- Assessing Patient Compliance: Drug concentrations can indirectly reflect adherence to a prescribed regimen.
- Evaluating Organ Function: Metabolism and excretion depend on liver and kidney function, so shifts in PK parameters can indicate the functional status of those organs.
Underpinning these applications is the often strong correlation between drug concentration and pharmacological effect. Concentration at the actual site of action, such as receptors in a specific tissue, reflects the effect most directly, but those sites are usually inaccessible for sampling. With digoxin, which acts on the myocardium, routinely obtaining heart tissue is not feasible. Monitoring concentration in an accessible matrix such as blood/plasma (the most common choice, see Fig. 1-1), urine or saliva gives an indirect read on exposure at the target.
The concept supporting that inference is Kinetic Homogeneity. It postulates that, in most cases, a predictable proportional relationship exists between drug concentration in plasma (or blood) and concentration at the target tissue or receptor site (Fig. 1-2). A change in plasma concentration then reflects a parallel change in tissue concentration: as plasma levels rise, most tissues follow proportionally, and the same holds in reverse (Fig. 1-3 shows a simplified illustration).
Which parameters can be estimated follows from the sampling schedule rather than from the assay. Cmax and Tmax depend on early time points around the peak, AUC depends on coverage across both the absorption and the elimination phase, and half-life depends on sampling far enough into the terminal phase for the slope to be defined. A schedule that misses the absorption phase will describe the decline accurately and the peak poorly, and no amount of modeling recovers the missing information.
Kinetic homogeneity is a working assumption behind clinical pharmacokinetics and behind the design of preclinical PK studies. It allows a team to set therapeutic windows and toxicity thresholds from plasma concentrations that are easy to measure. The assumption does not hold for every drug. Physicochemical properties such as molecular size, lipophilicity and ionization can drive preferential accumulation in a particular tissue. Digoxin concentrates in the myocardium; highly lipophilic drugs such as benzodiazepines tend to accumulate in adipose tissue. Knowing which behavior applies is part of interpreting PK data correctly, and it is one of the factors the Prisys Biotech team weighs when designing preclinical PK studies, including those run on the NHP Pharmacology of Prisys Biotech platform.
II. Pharmacodynamics (PD) Research: Unveiling Drug Mechanism and Effect
Pharmacodynamics (PD) covers the quantitative relationship between drug concentration and response, counting both therapeutic effects and adverse reactions, with their intensity and time course. Effects begin with binding to a specific target, usually a receptor. Targets sit in many places: on neurons in the central nervous system, where opioid receptors mediate analgesia; on myocardial cells, where they influence contractility; or inside pathogens, as with antibiotics that disrupt bacterial cell wall synthesis.
In simplified models, drug concentration at the site of action dictates the intensity of the pharmacological effect (Fig. 1-4). Real responses are modulated by several factors:
- The density and number of receptors on the cell surface.
- The efficiency of intracellular signal transduction pathways (second messenger systems).
- Downstream regulatory mechanisms involving gene transcription and protein synthesis.
These biological factors produce inter-individual variability in drug response and can lead to potentiation or tolerance, so the same individual may respond differently over time. That variability is the reason PD work is run in models that reproduce human physiology closely, and why PD services are usually paired with exposure data rather than read in isolation.
Testing across a sufficiently wide concentration range allows the maximum effect (Emax) to be determined. Plotting concentration, often after logarithmic transformation, against effect yields the characteristic dose-response or concentration-effect curve, with a threshold concentration above which the effect plateaus (Fig. 1-5).
Curve shape carries information that a single potency value does not. A steep curve means small changes in exposure produce large changes in effect, which narrows the usable dosing margin. A shallow curve tolerates variability between individuals better, but it may never reach a clear maximum inside a feasible dose range, and the reported Emax then describes the tested range rather than the drug.
A common metric for comparing potency is the Half-maximal Effective Concentration (EC50), the concentration that produces 50% of the Emax. Between two drugs, the one with the lower EC50 is more potent, meaning a smaller dose reaches the same level of effect.
EC50 describes potency only. It says nothing about clinical superiority and carries no information about how long an effect lasts. Duration is a more complex parameter, set by drug-receptor binding kinetics and by how long downstream signaling persists.
Tolerance is the decline in effect during continuous administration. It can be pharmacokinetic, as when metabolism accelerates and concentrations fall at a given dose, or pharmacodynamic, as when receptors downregulate or desensitize so that the same concentration produces less effect. Patients on chronic opioid therapy for pain often need dose escalation to hold analgesia. On a concentration-effect plot, tolerance appears as a rightward shift of the curve (Fig. 1-6). Tachyphylaxis is a distinct form with rapid onset, where raising the dose often fails to restore the effect, although responsiveness may return after a drug-free interval.
Clinical Considerations and the Value of Prisys Biotech Services
Three practical questions follow from the pharmacology above, and each shapes how a preclinical package is built.
Tolerance Management
Understanding tolerance mechanisms changes clinical strategy. Continuous use of organic nitrates such as nitroglycerin for angina can produce tachyphylaxis, and intermittent dosing with a "nitrate-free interval" is used clinically to preserve efficacy. With opioids, analgesia has to be balanced against tolerance and dependence risk. Slow dose titration sometimes lets a patient develop physiologic tolerance to certain side effects, which in turn allows higher therapeutic doses. That is distinct from psychological dependence, the subjective craving for the drug. For a preclinical program, the practical consequence is that dosing duration has to match the question: a single-dose study cannot detect tolerance, and a chronic study built around a tolerance endpoint needs a sampling schedule long enough to see the shift. Withdrawal raises the mirror question. When a receptor population has adapted, removing the drug can let the effect overshoot baseline before it settles, which is why tapering schedules exist for several classes that act on adaptive receptors.
Potency vs. Clinical Choice
Potency reflects the amount of drug needed for a given effect. A more potent drug is not automatically a better one; it means a lower dose may be required, which matters for formulation, cost and exposure limits. Given at equipotent doses, two drugs should show similar primary efficacy. Clinical selection weighs efficacy, safety, convenience and cost together.
The Central Role of PK/PD in Drug Development
The integration of pharmacokinetics and pharmacodynamics in drug development turns two separate datasets into one exposure-response argument. That argument predicts effective dose ranges in humans, supports dosing regimen design, and provides the pharmacology section of an Investigational New Drug (IND) application.
Model form is a practical choice rather than a formality. A simple Emax relationship may be enough where the data define a plateau cleanly; a sigmoid Emax form with a slope term is used when the transition between minimal and maximal effect is abrupt. When concentration and effect are measured at different times, or when the response depends on a downstream process that lags behind receptor occupancy, an indirect response model usually describes the data better than a direct one, because it allows for the delay explicitly.
Prisys Biotech runs preclinical PK/PD programs built around those questions. The work covers pharmacokinetic parameter determination, pharmacodynamic assessment, biomarker analysis and PK/PD relationship studies, using analytical methods matched to the molecule and animal models matched to the question. NHP models carry much of the load here because their physiology, immune system and target homology sit close to humans, which matters when an exposure-response relationship established in animals has to support a human dose.
Conclusion
PK and PD describe drug action from two directions, and development decisions depend on both being measured well. Dose selection, safety margins and the design of a first-in-human trial all rest on study data that connect concentration to effect in a species that predicts human behavior.
Prisys Biotech works on that connection from study design through data interpretation, with Prisys' Nonhuman Primate Disease Models providing the efficacy side of the picture. Two constraints shape the work. PD endpoints have to be measurable repeatedly in a living animal without disturbing the disease course, and the biomarker chosen has to move with the mechanism rather than with handling stress. Programs that need pharmacokinetic characterization, pharmacodynamic endpoints and a defensible exposure-response story can discuss scope and design with the team directly.
